Financial Shenanigans

Financial Shenanigans — Molina Healthcare (MOH)

1. The Forensic Verdict

Molina earns an Elevated (55/100) forensic risk grade. The income statement, cash flow statement, and disclosure record all show real strain in 2025, but the strain so far is consistent with a managed-care company that misjudged medical-cost trend, not with systematic accounting fabrication. The two concerns that drive the grade up are (i) an unprecedented operating cash outflow of $535 million in a year of 12% revenue growth, alongside debt-funded buybacks, and (ii) a thicket of external accountability events — a $40 million Texas AG Medicaid-fraud settlement, a securities class action filed November 2025 over medical-cost-trend disclosures, three guidance cuts in 2025, and the forfeiture of 2025 short-term incentive payouts and 2023 PSUs. The two concerns that hold the grade down from "High" are a clean auditor record (Ernst and Young, no material weakness, no restatement, no late filing) and a clawback regime that is visibly working — incentive payouts were zeroed before any restatement was needed. The single data point that would most change the grade is whether the 2026 10-K shows favorable or unfavorable prior-period claim reserve development against the FY2025 booked liability. Significant favorable PPD would reduce concern that 2025 reserves were under-set; significant unfavorable PPD would push the grade toward High.

Shenanigans scorecard

2. Breeding Ground

The breeding ground is mixed: the incentive plan favors aggressive adjusted-EPS reporting, but the governance machinery around it is responsive and the auditor relationship is uneventful.

• The CEO's long-term equity (60% of LTI) is tied to cumulative adjusted EPS over a three-year window. The annual short-term incentive is tied to adjusted EPS. Both create incentive to lean into favorable reserve assumptions and to defend guidance in flight.
• The plan worked in reverse in 2025: 2025 STIP non-equity incentive payouts were $0 across all named executives, 2023 PSUs were forfeited without payment, and 2024/2025 PSU grants are at or near zero fair value. The committee did not invent discretionary bonuses to backfill.
• The auditor is Ernst and Young, long tenure, no qualifications, no late filings, no material weakness disclosed. The audit committee includes Barbara Brasier (former Herc Rentals CFO, CPA) and Steven Orlando (finance/audit background).
• The board is 10 members, independent majority, separate Chairman (Schapiro since 2021). No founder/promoter overhang; the Molina family no longer runs the company (CEO Joseph Zubretsky has been in place since 2017).
• A clawback policy effective October 2023 covers restatement-driven recovery regardless of executive misconduct.
• A history streak of beating expectations broke decisively in 2025: three downward guidance revisions, a full-year result $13.47 below the initial $24.50 adjusted EPS guide. Multiple plaintiff firms initiated securities investigations; one class action has been filed.
• Insider buying picked up in early 2026 (CFO, COO, EVP, Chief Legal Officer all purchased shares) — a counter-signal to the litigation narrative.

The breeding ground does not look like a fraud setup. It looks like a normal aggressive-EPS plan that hit a year where the medical-cost-trend assumption embedded in guidance turned out to be too optimistic. The structural defenses (clawback, independent board, EY auditor, no founder dominance) functioned in 2025. The single live unknown is whether the disclosures inside the Class Period (Feb 5 to July 23, 2025) crossed from "wrong" to "knowingly misleading" — that is what the class action and the related plaintiff-firm investigations will be testing.

3. Earnings Quality

Earnings quality deteriorated sharply in 2025, but the deterioration is dominated by under-reserving for medical costs rather than aggressive revenue or capitalization choices. The income statement is honest about the damage: GAAP operating income fell from $1,707M to $781M on revenue that grew $4.8B.

The Medicare segment MCR moved from 89.1% to 92.4%. The Marketplace segment MCR moved from 75.4% to 90.6% in a single year — a 1,520 basis-point reset on a $4.5 billion premium base. The Medicaid segment MCR moved from 90.3% to 91.8%, with an "unfavorable retroactive premium" item in California recognized in Q4 2025 worth roughly $2 per share. A move of this magnitude in one segment, layered on top of late-quarter retroactive adjustments in another, is the forensic signature of a reserve that was set too lightly in prior periods and had to be made whole at year end. Management acknowledges this in plainer language during the Q4 2025 call ("rates have not kept up with trend over the past 6 quarters") than during the Q1 and Q2 2025 calls, which is the time-window the securities complaint focuses on.

Receivables and DSO are clean

DSO sits in the 25–29 day band and is consistent with a managed-care payor whose receivables are mainly government premium and pharmacy rebate balances. The one anomaly is FY2023, when receivables grew 34.8% against 6.6% revenue growth — a 28-percentage-point spread. That coincided with the Medicaid redetermination cycle and risk-corridor receivables under the Marketplace risk-adjustment program. The spread compressed in FY24 and FY25 without an apparent write-down, which is mildly reassuring but worth tracking.

Capitalization and goodwill drift

Goodwill has grown from $1,252M (FY21) to $2,195M (FY25) on roughly $850M of cumulative net acquisition cash (My Choice Wisconsin 2022, Bright Health Medicare Advantage assets 2024, ConnectiCare February 2025). With FY25 operating income at $781M and a market capitalization-to-equity ratio that has compressed, the impairment-trigger test becomes a watch item for the FY26 audit, particularly for the Bright Health Medicare Advantage assets given the planned MAPD product exit for 2027.

Capex remains tiny — $101M in FY25 against $195M of depreciation and amortization (0.52x). That ratio has been stable for five years, so there is no evidence Molina is depreciating slowly. But depreciation running 2x capex while goodwill grows is the classic pattern of a managed-care platform whose growth is increasingly purchased rather than built. No impairment was recorded in FY25 despite operating income falling 54%.

Other income and tax leverage

Operating income of $781M in FY25 is supported by $420M of investment income (52%). The effective tax rate dropped from 25.8% to 19.8% on the strength of "transferable federal tax credits." Together these two items move roughly $200M of pretax earnings that would not repeat at historical rates. None of this is wrong — it is disclosed — but a reader who looks only at "adjusted EPS" of $11.03 should net out the tax tailwind and the investment-income contribution before extrapolating margin.

4. Cash Flow Quality

Cash-flow quality broke in 2025. This is the single most important forensic fact in the file.

Over the five years FY21–FY25, cumulative CFO of $4,663M roughly tracks cumulative net income of $4,193M (1.11x ratio), which is in-range for a managed-care payor. But the three-year ratio degraded to 0.65x because of the FY24 and FY25 collapses, and the trailing-year ratio is negative.

Management's own reconciliation in the FY25 management discussion section attributes the $1,179 million year-over-year CFO swing to (i) lower operating income, (ii) "timing differences in settlement of government agency receivables and payables, including settlements for Medicaid minimum MLR and medical cost corridors and Marketplace risk adjustment payables," and (iii) the timing of tax payments. The honest read is that approximately half of the swing is operational (lower NI) and half is timing within the working-capital cycle of government insurance.

Working-capital and supplier-finance check

Accounts payable declined $238M in FY25 to $1,093M, from $1,331M in FY24. Receivables rose $234M to $3,533M. Both moves drain CFO and neither is the cosmetic lever one would use to flatter cash flow. There is no disclosed factoring, securitization, supplier-finance program, or off-balance-sheet financing — the FY25 management discussion section explicitly states the company is "not a party to any off-balance sheet financing arrangements."

Acquisition-adjusted FCF

This is the chart institutional investors should keep open. Free cash flow after acquisitions ran $1.9B in FY21, $1.6B in FY23, $200M in FY24, and negative $881M in FY25. Over the same period, Molina repurchased $1.0B of stock in both FY24 and FY25 and issued $1.94B of new debt in FY25 ($1.04B in credit-facility borrowings since repaid and $850M of 6.500% senior notes due 2031 issued in November 2025). The result is that capital returns to shareholders in FY25 were financed entirely by net new debt — a configuration the rating agencies and the New Credit Agreement's covenant covenant counterparties have already noticed. Molina amended the credit agreement on February 4, 2026 to temporarily relax the minimum Interest Coverage Ratio through 2027.

Sustainability test

The 6.5% accrual ratio in FY25 (NI minus CFO, divided by average total assets) is large by any sector standard and is the cleanest single-number summary of the gap between reported earnings and reported cash. The Beneish-style read on this is "watch list," not "definitive earnings manipulation," because the gap is explained by a known, disclosed, operating cause — government program receivable and payable timing.

5. Metric Hygiene

Disclosure hygiene is average for managed care. The MCR, general and administrative expense ratio, days-in-claims-payable, and pretax margin are all reported consistently. The headline forensic issues are with "adjusted EPS," "embedded earnings," and the late-quarter "retroactive" framing.

Three observations:

1. The adjusted-EPS gap is modest ($11.03 vs $8.92 = $2.11). The reconciling items (acquisition costs, amortization of acquired intangibles, debt-extinguishment charges) are conventional managed-care adjustments. The gap is not the issue. The issue is that the PSU plan rewards cumulative adjusted EPS over three years, which creates a multi-year incentive to defend the metric.

2. "Embedded earnings" of more than $11 per share is a forward-looking management construct. It assumes new contracts (Florida CMS for $6B in premium starting Q4 2026, Georgia Star-Chip and Texas Star-Chip starting 2027, Illinois HealthChoice starting 2027) reach target margins. The figure should not be combined with reported EPS in any valuation framework, and it is not derivable from the financial statements.

3. The Q4 2025 framing of California Medicaid items as "retroactive" is legitimate accounting language for end-of-period rate corridor and risk-adjustment settlements. But the timing pattern — large negative items appearing in the quarter where management has the most pressure to defend full-year guidance — is the kind of pattern the class-action plaintiff complaint focuses on. Forensically, this is a disclosure-timing question, not a recognition-period question.

6. What to Underwrite Next

The next four quarters of disclosure will resolve most of the open forensic questions. The diligence checklist is concrete:

1. Prior-period reserve development in the FY2026 10-K Note 10 ("Medical Claims and Benefits Payable"). Watch the development of the FY2025 booked liability. Unfavorable PPD would confirm under-reserving in 2025. Favorable PPD would partly disprove it. This is the single most decision-relevant number for forensic risk.
2. Cash flow from operations in 1H 2026. Management has flagged "much more front-end loaded" earnings in 2026 (two-thirds in 1H). If CFO does not recover at least to the FY24 level ($644M annualized) by mid-year, the FY25 outflow is harder to dismiss as a one-time timing event.
3. Securities class action progress in the C.D. Cal. docket (Hindlemann v. Molina Healthcare). Motion-to-dismiss briefing typically runs to mid-2026. Survival would shift the litigation reserve calculation. Dismissal would close one of the live risk items.
4. Goodwill impairment testing. With operating income down 54% and the MAPD product slated for exit in 2027, the Bright Health Medicare Advantage portion of goodwill is the highest-probability impairment candidate. Any impairment in 2026 would not be a fraud signal — it would be the system working — but the size of the charge matters for the FY26 GAAP-vs-adjusted bridge.
5. Audit committee disclosure language in the 2026 proxy about (a) the EY engagement, (b) critical audit matters, and (c) any rotation of the lead audit partner. A change here that is not routine would be a material upgrade in concern.

What would downgrade the grade to Watch: favorable PPD on the FY25 reserve, CFO above $1.0B in 1H 2026, dismissal of the securities class action, no goodwill impairment, and re-engagement of EY without qualification.

What would upgrade the grade to High: a restatement, a material weakness, denial of the motion to dismiss with adverse findings on the disclosure question, unfavorable PPD on the FY25 reserve of more than 100 basis points of premium revenue, a goodwill impairment of more than $500M, or any change in audit firm under unfavorable circumstances.

This forensic work should affect position sizing and required margin of safety, not the thesis itself. The accounting risk is not a thesis-breaker — Molina is auditing the right things, disclosing the right reconciliations, and the clawback regime fired correctly in 2025. But the combination of debt-funded buybacks against a negative-FCF year, a known regulatory finding in Texas, and pending securities litigation tied to mid-year guidance disclosures means the equity should price for a higher hurdle than peers. An institutional investor underwriting MOH at current levels should size to allow for a goodwill impairment of $300–500M, a litigation reserve build, and the possibility that 2026 reserves are again set at the low end of management's actuarial range.